Learn how colon cancer patients can reap the benefits of exercise, potentially raising the chances of survival post-surgery ...

A structured exercise program after surgery and adjuvant chemotherapy reduced the risk for cancer recurrence and death for certain patients with colon cancer, according to study results presented at ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

As cancer drug deaths pile up, doctors are increasingly testing for gene variants that can cause thousands of patients to ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

Two studies presented at ASCO's annual meeting used ctDNA testing to determine which patient might benefit from anti-EGFR retreatment.

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Amgen Inc. (NASDAQ: AMGN )’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.